Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate

• Verfasst von: Bonekamp, David [VerfasserIn]
• Verfasst von: Röthke, Matthias C. [VerfasserIn]
• Verfasst von: Pahernik, Sascha [VerfasserIn]
• Verfasst von: Hatiboglu, Gencay [VerfasserIn]
• Verfasst von: Hohenfellner, Markus [VerfasserIn]
• Verfasst von: Schlemmer, Heinz-Peter [VerfasserIn]
• Verfasst von: Wolf, Maya Barbara [VerfasserIn]
• Titel: Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate
• Verf.angabe: David Bonekamp, M.B. Wolf, M.C. Roethke, S. Pahernik, B.A. Hadaschik, G. Hatiboglu, T.H. Kuru, I.V. Popeneciu, J.L. Chin, M. Billia, J. Relle, J. Hafron, K.R. Nandalur, R.M. Staruch, M. Burtnyk, M. Hohenfellner, H.-P. Schlemmer
• Jahr: 2019
• Jahr des Originals: 2018
• Umfang: 10 S.
• Fussnoten: Published online: 25 June 2018 ; Gesehen am 01.08.2019
• Titel Quelle: Enthalten in: European radiology
• Ort Quelle: Berlin : Springer, 1991
• Jahr Quelle: 2019
• Band/Heft Quelle: 29(2019), 1, Seite 299-308
• ISSN Quelle: 1432-1084
• ISSN Quelle: 1613-3757
• DOI: doi:10.1007/s00330-018-5584-y
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Biopsy
• Sach-SW: High-intensity focused ultrasound ablation
• Sach-SW: Interventional magnetic resonance imaging
• Sach-SW: needle
• Sach-SW: Prostate cancer
• Sach-SW: Thermometry
• K10plus-PPN: 1669147789

Abstract

PurposeTo quantitatively assess 12-month prostate volume (PV) reduction based on T2-weighted MRI and immediate post-treatment contrast-enhanced MRI non-perfused volume (NPV), and to compare measurements with predictions of acute and delayed ablation volumes based on MR-thermometry (MR-t), in a central radiology review of the Phase I clinical trial of MRI-guided transurethral ultrasound ablation (TULSA) in patients with localized prostate cancer.Materials and methodsTreatment day MRI and 12-month follow-up MRI and biopsy were available for central radiology review in 29 of 30 patients from the published institutional review board-approved, prospective, multi-centre, single-arm Phase I clinical trial of TULSA. Viable PV at 12 months was measured as the remaining PV on T2-weighted MRI, less 12-month NPV, scaled by the fraction of fibrosis in 12-month biopsy cores. Reduction of viable PV was compared to predictions based on the fraction of the prostate covered by the MR-t derived acute thermal ablation volume (ATAV, 55°C isotherm), delayed thermal ablation volume (DTAV, 240 cumulative equivalent minutes at 43°C thermal dose isocontour) and treatment-day NPV. We also report linear and volumetric comparisons between metrics.ResultsAfter TULSA, the median 12-month reduction in viable PV was 88%. DTAV predicted a reduction of 90%. Treatment day NPV predicted only 53% volume reduction, and underestimated ATAV and DTAV by 36% and 51%.ConclusionQuantitative volumetry of the TULSA phase I MR and biopsy data identifies DTAV (240 CEM43 thermal dose boundary) as a useful predictor of viable prostate tissue reduction at 12 months. Immediate post-treatment NPV underestimates tissue ablation.Key Points • MRI-guided transurethral ultrasound ablation (TULSA) achieved an 88% reduction of viable prostate tissue volume at 12 months, in excellent agreement with expectation from thermal dose calculations. • Non-perfused volume on immediate post-treatment contrast-enhanced MRI represents only 64% of the acute thermal ablation volume (ATAV), and reports only 60% (53% instead of 88% achieved) of the reduction in viable prostate tissue volume at 12 months. • MR-thermometry-based predictions of 12-month prostate volume reduction based on 240 cumulative equivalent minute thermal dose volume are in excellent agreement with reduction in viable prostate tissue volume measured on pre- and 12-month post-treatment T2w-MRI.